Evidence map›Paper›PMID 35220716›Full record

ReviewACS infectious diseases2022

Aptamers for Viral Detection and Inhibition.

Banani Chakraborty, Sreyashi Das, Arushi Gupta, Yanyu Xiong, Vyshnavi T-V, Megan E Kizer, Jinwei Duan, Arun Richard Chandrasekaran, Xing Wang

Abstract readReview
In one paragraph

Review in ACS infectious diseases, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Advances in Aptamer Drug Delivery Systems for Treatment of Glioblastoma.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026
    Review
  3. Review
  4. Review
  5. Article
  6. Review
  7. Review
  8. Article
  9. Article
  10. Article
  11. Review
  12. Review
  13. Article
  14. Article
  15. Article
  16. Review
  17. Review
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Banani ChakrabortyDepartment of Chemical Engineering, Indian Institute of Science, Bangalore, Karnataka 560012, India.
Sreyashi DasDepartment of Biological Sciences and Bioengineering, Indian Institute of Technology, Kanpur, Uttar Pradesh 208016, India.
Arushi GuptaDepartment of Chemical Engineering, Indian Institute of Science, Bangalore, Karnataka 560012, India.
Yanyu XiongDepartment of Electrical and Computer Engineering, University of Illinois at Urbana─Champaign, Urbana, Illinois 61801, United States.
Vyshnavi T-VDepartment of Chemical Engineering, Indian Institute of Science, Bangalore, Karnataka 560012, India.
Megan E KizerDepartment of Biology, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, United States.ORCID 0000-0003-3549-8606
Jinwei DuanDepartment of Chemistry and Materials Science, Chang'an University, Xi'an, Shaanxi 710064, China.
Arun Richard ChandrasekaranThe RNA Institute, University at Albany, State University of New York, Albany, New York 12222, United States.ORCID 0000-0001-6757-5464
Xing WangNick Holonyak Jr. Micro and Nanotechnology Laboratory (HMNTL), University of Illinois at Urbana─Champaign, Urbana, Illinois 61801, United States.ORCID 0000-0001-9930-3287

Funding

Ultrasensitive HIV viral load quantitation using designer DNA nanostructure capture probes and photonic resonator interference scattering microscopyR01AI159454 · NIAID · STANFORD UNIVERSITY · PI CUNNINGHAM, BRIAN T., DEMIRCI, UTKAN · 2021 to 2025
$3.6M
Designer DNA Nanostructure Based Biosensing for Rapid COVID19 Detection and Monitoring using Saliva SampleR44DE030852 · NIDCR · ATOM BIOWORKS INC · PI YAO, XIAOHU · 2021 to 2022
$1.7M
Detection and Automatic Privacy-Protected Contact Tracing System Designed for COVID-19U01AA029348 · NIAAA · UNIVERSITY OF ILLINOIS AT URBANA-CHAMPAIGN · PI PENG, LU, WANG, XING · 2021 to 2023
$1.4M
Developing glycan-directed tools to investigate microbial infectionF32GM137477 · NIGMS · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI KIZER, MEGAN E · 2020 to 2022
$170k
NIAAA NIH HHS U01 AA029348NIAID NIH HHS R01 AI159454NIDCR NIH HHS R44 DE030852NIGMS NIH HHS F32 GM137477
6 · The paper itself

Abstract

Recent times have experienced more than ever the impact of viral infections in humans. Viral infections are known to cause diseases not only in humans but also in plants and animals. Here, we have compiled the literature review of aptamers selected and used for detection and inhibition of viral infections in all three categories: humans, animals, and plants. This review gives an in-depth introduction to aptamers, different types of aptamer selection (SELEX) methodologies, the benefits of using aptamers over commonly used antibody-based strategies, and the structural and functional mechanism of aptasensors for viral detection and therapy. The review is organized based on the different characterization and read-out tools used to detect virus-aptasensor interactions with a detailed index of existing virus-targeting aptamers. Along with addressing recent developments, we also discuss a way forward with aptamers for DNA nanotechnology-based detection and treatment of viral diseases. Overall, this review will serve as a comprehensive resource for aptamer-based strategies in viral diagnostics and treatment.

Indexed as

Aptamers, NucleotideBiosensing TechniquesVirus DiseasesVirusesAnimalsNanotechnologyAptamers, NucleotideaptamersaptasensorsDNA nanostructuresinhibitionsensingviruses

Identifiers

PMID35220716
PMCPMC8905934

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.